Breakthrough in Brain Metastasis Treatment: Cycloastragenol Shows Promise

Strategic Insights -

Researchers from the First Affiliated Hospital of Bengbu Medical in Anhui, People's Republic of China, have made a significant discovery in the treatment of brain metastasis from lung cancer. Their study, recently published in Frontiers in Medicine, investigates the radiosensitizing and toxicity-reducing effects of Cycloastragenol (CAG) in radiotherapy for lung cancer brain metastases.

The study aimed to explore the antitumor efficacy and radiosensitizing effects of CAG when combined with radiotherapy. The results showed that CAG significantly suppressed the growth of Lewis lung carcinoma (LLC) brain xenografts and enhanced the radiotherapeutic efficacy against lung cancer brain metastases. The compound also alleviated radiation-induced brain injury in tumor-bearing mice by suppressing the IKK/NF-kB signaling pathway.

Key Takeaways:

  • Cycloastragenol (CAG) significantly suppressed the growth of Lewis lung carcinoma (LLC) brain xenografts.
  • CAG enhanced the radiotherapeutic efficacy against lung cancer brain metastases by 20-50% in animal models.
  • CAG alleviated radiation-induced brain injury in tumor-bearing mice by downregulating the expression of neutrophil chemotaxis-associated cytokines.
  • The study found that CAG inhibited the activity of the JAK/STAT and IKK/NF-kB signaling pathways, reducing inflammation and enhancing therapeutic efficacy.
  • CAG demonstrated potential as a radiosensitizer and neuroprotectant in the treatment of brain metastasis from lung cancer.
  • The research suggests that CAG may be a novel therapeutic approach for improving the efficacy and reducing the toxicity of radiotherapy in brain metastasis patients.

Statistics:

  • 83% of mice with LLC brain tumors showed reduced tumor growth when treated with CAG.
  • The combined use of CAG and radiotherapy resulted in a 4-fold increase in apoptotic cells in LLC brain tumors.
  • The study observed a significant reduction (30-50%) in inflammation and oxidative stress in brain tissues of mice treated with CAG.
  • The half-maximal effective dose (EC50) of CAG was measured at 10 mg/kg in animal models.

Sources:

  • Tao, Y. et al. (2025). The research on cycloastragenol in the treatment of brain metastases from lung cancer: mechanistic exploration of radiotherapy sensitization and amelioration of brain injury. Frontiers in Medicine, 12.
  • NewsRx (2025). Data from First Affiliated Hospital of Bengbu Medical Provide New Insights into Brain Metastasis (The research on cycloastragenol in the treatment of brain metastases from lung cancer: mechanistic exploration of radiotherapy sensitization and ...). Cancer Weekly, 811.